Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| IRCCS National Neurological Institute "C. Mondino" Foundation | OTHER |
| Società Italiana per lo Studio delle Cefalee | OTHER |
| Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
Rimegepant belongs to the gepants family, small molecules calcitonin gene-related peptide (CGRP) receptor antagonists. It is a new generation gepants, currently available as an orally disintegrating tablet at a single dose of 75 mg. It has a double indication both for acute treatment for migraine with and without aura and preventive treatment of episodic migraine. Previous randomized, placebo-controlled phase 3 trials and open label extensions demonstrated its effectiveness in the acute setting for a single migraine attack of both the oral tablet and the orally disintegrating tablet. Pooled analysis of previous randomized clinical trials also showed rimegepant effectiveness in patients with a history of insufficient response to triptans.
Previous studies also demonstrated a good tolerability profile. The most commonly reported adverse events were nausea, nasopharyngitis, upper respiratory tract infections and urinary tract infection.
In this prospective multicentric study we aim to evaluate Rimegepant effectiveness and tolerability as acute migraine treatment in a real-world setting.
Subjects who meet the inclusion criteria will be enrolled and will participate in the study. Baseline demographic and clinical data will be collected at the baseline. Patients will be asked to treat their next migraine attack with Rimegepant 75 mg orally disintegrating tablet.
Data will be collected at baseline, during at least 4 migraine attacks treated with Rimegepant and at 3 months follow-up.
Subjects will be asked to complete assessment of their migraine attack at baseline and at 30 - 60 - 90 and 120 minutes after administration of the acute treatment for at least four migraine attacks. A final timepoint at 24 hours post-dose will be assessed only for the first attack.
Data collection will focus on: i) demographic data, ii) migraine history, iii) pain level and evolution, iv) presence and evolution of migraine associated symptoms, most bothersome symptom and aura, v) migraine associated disability, vi) patients's global impression of change (PGIC) and evaluation on the acute treatment (Migraine-ACT), vii) tolerability and eventual treatment-emergent adverse events. The online database REDCap will be used for data collection.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Episodic migraine | Patients affected by an episodic pattern migraine(< 15 monthly headache days) with or without aura according to ICHD-III criteria. |
| |
| Chronic migraine | Patients affected by chronic migraine according to ICHD-III criteria. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rimegepant 75 MG Disintegrating Oral Tablet | Drug | Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Headache pain freedom at 2 hours post-dose during the first attack | The percentage of subjects that report no headache pain at 2 hours after drug intake. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). | 2 hours post-dose |
| Occurrence of treatment-emergent adverse events | To evaluate the safety and tolerability of Rimegepant in migraine subjects. | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Headache pain freedom at 2 hours post-dose across all treated attacks | The percentage of subjects that report no headache pain at 2 hours after drug intake across all' treated attacks. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). | 2 hours post-dose for all treated attacks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Multicentric study on patients attending the outpatient clinic of Italian Headache centres who meet criteria for Rimegepant use for acute migraine treatments.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Luigi F Iannone, MD | Contact | +393896969606 | luigifrancesco.iannone@unifi.it | |
| Roberto De Icco, MD | Contact | roberto.deicco@mondino.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi | Recruiting | Florence | 50134 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31291516 | Background | Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090. | |
| 31311674 | Background | Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| D020325 | Migraine with Aura |
| D020326 | Migraine without Aura |
| D006261 | Headache |
| D051271 | Headache Disorders, Secondary |
| D010146 | Pain |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C578443 | rimegepant sulfate |
Not provided
Not provided
Not provided
| Università degli Studi dell'Aquila | OTHER |
| University of Roma La Sapienza | OTHER |
| Azienda Ospedaliero Universitaria Policlinico Modena | OTHER |
| Ospedale di Piove di Sacco | UNKNOWN |
| Azienda Ospedaliero-Universitaria di Parma | OTHER |
| Azienda Ospedaliera S. Maria della Misericordia | OTHER |
| A.O.U. Città della Salute e della Scienza | OTHER |
| Cliniche Humanitas Gavazzeni | OTHER |
| University of Campania Luigi Vanvitelli | OTHER |
| Ospedale Santo Stefano | OTHER |
| Azienda Policlinico Umberto I | OTHER |
| Auxologico San Luca | OTHER |
| Asst Degli Spedali Civili Di Brescia | OTHER |
| Carlo Besta Neurological Institute | OTHER |
Not provided
Not provided
Not provided
| Headache pain relief at 2 hours post-dose during the first attack |
The percentage of subjects that report mild or none headache pain at 2 hours after drug intake during the first attack. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). |
| 2 hours post-dose |
| Headache pain relief at 2 hours post-dose across all treated attacks | The percentage of subjects that report mild or none headache pain at 2 hours after drug intake across all treated attack. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). | 2 hours post-dose for all treated attacks |
| Ability to function normally at 2 hours post-dose during the first attack | The percentage of subjects that self-report no functional disability at 2 hours post-dose. Functional disability will be assessed through the Functional Disability Scale (FDS), a four-point scale: normal, mildly impaired, severely impaired, requires daily activities interruption. | 2 hours post-dose |
| Ability to function normally at 2 hours post-dose across all treated attacks | The percentage of subjects that self-report no functional disability at 2 hours post-dose. Functional disability will be assessed through the Functional Disability Scale, a four-point scale: normal, mildly impaired, severely impaired, requires daily activities interruption. | 2 hours post-dose for all treated attacks |
| Freedom from the most bothersome symptom (MBS) associated with migraine at 2 hours post-dose during the first attack | The percentage of subjects that report complete MBS resolution at 2 hours after drug intake. MBS will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). | 2 hours post-dose |
| Headache recurrence for the first-attack | Percentage of subjects who became pain free at 2 hours post-dose and report new headache pain within 24 hours post-dose. | between 2 hours and 24 hours post-dose |
| Rescue medications use for the first attack | Percentage of subjects who take a rescue medication after 2 hour post-dose. Rescue medications will be measured using a binary scale (0=no consumption, 1=consumption) | between 2 hours and 24 hours post dose |
| Treatment satisfaction | Level of patients' self-reported satisfaction which will be measured on a 0-10 visual analogue scale (0=no satisfaction, 10= the highest satisfaction) and Patients Global Impression of Change (0= no changing, 7= a change that makes the difference). | 2 hours post-dose for all treated attacks |
| Self-reported treatment effectiveness | Level of patients' self-reported treatment effectiveness measured by Migraine Assessment of Current Therapy (Migraine-ACT) a 4-item questionnaire about treatment effectiveness and daily life repercussions. | 12 weeks |
| IRCCS National Neurological Institute "C. Mondino" Foundation | Recruiting | Pavia | 27100 | Italy |
|
| 36739511 | Background | Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L'Italien G, Morris BA, Coric V, Goadsby PJ. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023 Feb;43(2):3331024221141686. doi: 10.1177/03331024221141686. |
| 39762740 | Derived | Iannone LF, Vaghi G, Sebastianelli G, Casillo F, Russo A, Silvestro M, Pistoia F, Volta GD, Cortinovis M, Chiarugi A, Montisano DA, Prudenzano MP, Cevoli S, Mampreso E, Avino G, Romozzi M, Valente M, Fasano C, Battistini S, Granato A, Piella EM, Rainero I, Ornello R, De Icco R; Italian Headache Registry (RICe) Study Group. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J Headache Pain. 2025 Jan 6;26(1):4. doi: 10.1186/s10194-024-01935-8. |
| D009422 | Nervous System Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |